Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.62 |
| ▸ | F2 | P00734 | 5/20 | 0.59 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1994271 | 0.91 | F10 (0.70) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL4593475 | 0.87 | F10 (0.66) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL4593373 | 0.87 | F10 (0.66) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL4603100 | 0.85 | F10 (0.83) | F10F2 | |
| SCHEMBL4618948 | 0.84 | F10 (0.63) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL4593745 | 0.84 | F10 (0.62) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL4585744 | 0.82 | F10 (0.79) | F10F2 | |
| SCHEMBL1996248 | 0.81 | F10 (0.76) | F10F2PDE4APDE4BPDE4C | |
| SCHEMBL4593164 | 0.81 | F10 (0.65) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL5641079 | 0.79 | F10 (0.82) | F10F2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603562-A4 | SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-22 | — | — | EP | claimed |
| US-7122557-B2 | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-17 | — | — | US | claimed |
| EP-1603562-A2 | SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-12-14 | — | — | EP | claimed |
| US-20040209863-A1 | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | claimed |
| WO-2004083174-A2 | SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | claimed |
| EP-1603562-A4 | SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7122557-B2 | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1603562-A2 | SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040209863-A1 | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | disclosed |
| WO-2004083174-A2 | SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209863-A1 | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | TFPI, SPINT2, TMPRSS4 | F10 37/4885F2 15/4885SLC29A1 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.